Loading data for DNA — first visit, this takes a few seconds.
Ginkgo Bioworks Inc. (DNA)
NYSE: DNA
· Real-Time Price · USD
7.71
+1.18 (18.07%)
At close: Aug 19, 2026, 8:00 PM
7.74
+0.39%
After-hours: 7:59 PM
Ginkgo Bioworks Inc. (DNA) Stock Price, Analysis & Data
18.07% (1D)
No data available
| Bid | 7.4 |
| Market Cap | 519.19M |
| Revenue (ttm) | 132.42M |
| Net Income (ttm) | -309.64M |
| Beta | 1.79 |
| EPS (ttm) | -5.33 |
| PE Ratio (ttm) | n/a |
| Forward PE | -2.66 |
| P/B (ttm) | 1.17 |
| P/S (ttm) | 3.92 |
| Earnings Date | n/a |
| Ask | 7.69 |
| Volume | 2,252,626 |
| Avg. Volume (20D) | 1,139,766 |
| Open | 6.98 |
| Previous Close | 6.53 |
| Day's Range | 6.98 - 7.75 |
| 52-Week Range | 5.37 - 17.58 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About DNA
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automat...
Industry Biotechnology
Sector Healthcare
IPO Date Apr 19, 2021
Employees 485
Stock Exchange NYSE
Ticker Symbol DNA
Website https://www.ginkgo.bio
Financial Performance
In 2025, Ginkgo Bioworks's revenue was 170.16M, a decrease of -25.06% compared to the previous year's 227.04M. Earnings were -312.76M, a decrease of -42.83%.
Financial StatementsEarnings Surprise
Ginkgo Bioworks has released their quarterly earnings on Aug 5, 2026: